ceralasertib   Click here for help

GtoPdb Ligand ID: 9390

Synonyms: AZD-6738 | AZD6738
Compound class: Synthetic organic
Comment: Ceralasertib (AZD6738) is an orally available small molecule inhibitor of ATR serine/threonine kinase [1-2]. AZD6738 induces cell death and senescence in cancer cells in vitro and enhances the therapeutic efficacy of cisplatin in xenograft models. In vivo, combining AZD6738 with cisplatin destroys ATM-deficient lung cancer xenografts.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 116.23
Molecular weight 412.17
XLogP 2.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1COCCN1c1cc(nc(n1)c1ccnc2c1cc[nH]2)C1(CC1)S(=O)(=N)C
Isomeric SMILES C[C@@H]1COCCN1c1cc(nc(n1)c1ccnc2c1cc[nH]2)C1(CC1)[S@@](=O)(=N)C
InChI InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
InChI Key OHUHVTCQTUDPIJ-JYCIKRDWSA-N
No information available.
Summary of Clinical Use Click here for help
ClinicalTrials.gov has a number of Phase 1 and 2 studies that are ongoing or being planned to evaluate the efficacy of AZD6738 alone or in combination with chemotherapy and/or novel anti-cancer agents. For example Phase 1/2 clinical trial NCT02264678 is evaluating AZD6738 in combination with other drugs, including carboplatin (platinum-based chemotherapy drug), olaparib (PARP inhibitor), and durvalumab (anti-PD-L1 immune checkpoint inhibitor), in a range of advanced solid tumours. Click here to view the entire list of AZD6738 trials on ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02264678 Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents Phase 1/Phase 2 Interventional AstraZeneca